O Krijgsman
Overview
Explore the profile of O Krijgsman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rozeman E, Hoefsmit E, Reijers I, Saw R, Versluis J, Krijgsman O, et al.
Nat Med
. 2021 Feb;
27(2):256-263.
PMID: 33558721
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo (...
2.
Theelen W, Krijgsman O, Monkhorst K, Kuilman T, Peters D, Cornelissen S, et al.
J Transl Med
. 2020 Jul;
18(1):271.
PMID: 32620126
Background: The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in dissecting the different components of the immune infiltrate....
3.
Kwakman R, de Cuba E, de Winter J, de Hingh I, Delis-van Diemen P, Tijssen M, et al.
Br J Cancer
. 2015 Feb;
112(5):851-6.
PMID: 25668003
Background: Patients with peritoneal metastases (PMs) originating from colorectal carcinoma (CRC) are curatively treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (MMC). We aim to...
4.
Belt E, te Velde E, Krijgsman O, Brosens R, Tijssen M, van Essen H, et al.
Ann Surg Oncol
. 2011 Oct;
19(4):1222-30.
PMID: 21989661
Background: Lymph node (LN) yield in colon cancer resection specimens is an important indicator of treatment quality and has especially in early-stage patients therapeutic implications. However, underlying disease mechanisms, such...
5.
Epping M, Hart A, Glas A, Krijgsman O, Bernards R
Br J Cancer
. 2008 Jul;
99(3):398-403.
PMID: 18648365
The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome...